WJ460 |
| Catalog No.GC38203 |
WJ460 es un potente inhibidor de mioferlina (MYOF), que interactÚa directamente con MYOF y ejerce una actividad antimetastÁsica en el rango nanomolar en las células de cÁncer de mama.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1415251-36-3
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
WJ460 is a potent myoferlin (MYOF) inhibitor, which interacts directly with MYOF and exerts anti-metastatic activity in the nanomolar range in breast cancer cells[1].
WJ460 blocks breast cancer cell invasion with IC50 values of 43.37 ± 3.42 nM in MDA-MB-231 and 36.40 ± 4.51 nM in BT549 cells. WJ460 treatment remarkably inhibits MDA-MB-231 and BT549 cell invasion through Collagen I in a dose-dependent manner[1].
WJ460 inhibits breast tumor growth, angiogenesis, and spontaneous metastasis in a spontaneous metastasis model[1].
[1]. Zhang T, et al. A small molecule targeting myoferlin exerts promising anti-tumor effects on breast cancer. Nat Commun. 2018 Sep 13;9(1):3726.
Average Rating: 5 (Based on Reviews and 28 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *